← Leaderboards
Patrick Walsh
University Of Colorado Denver
$572,093
Attributed
$572,093
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$572,093 · 2
By mechanism
M01$413,706 · 1
R01$158,387 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Donald Ym Leung$75,548,590
- Robert Turner Schooley$73,100,957
- Donald Bellgrau$4,610,601
- Andrew S Kraft$21,224,247
- Peter A Gottlieb$9,273,760
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical Trial Phase IGene TherapyHuman SubjectHuman Therapy EvaluationMelanomaMetastasisNeoplasm /Cancer ImmunotherapyStaphylococcal EnterotoxinSuperantigensNeoplasm /Cancer VaccineCombination Cancer TherapyInjection /InfusionInterleukin 2PlasmidsVector VaccineNeoplasm /Cancer TherapyNeoplasm /Cancer ImmunologyColony Stimulating FactorTissue /Cell CultureNeoplastic Growth
Grant awards (6)
PHASE I STUDY USING DIRECT COMBINATION DNA INJECTIONS FOR IMMUNOTHERAPY$190,747
M01 · FY2002 · RR
PHASE I STUDY USING DIRECT COMBINATION DNA INJECTIONS FOR IMMUNOTHERAPY$190,747
M01 · FY2001 · RR
PHASE I STUDY USING DIRECT COMBINATION DNA INJECTIONS FOR IMMUNOTHERAPY$0
M01 · FY2001 · RR
CLINICAL STUDIES OF GENE THERAPY FOR MELANOMA$158,387
R01 · FY2000 · CA
PHASE I STUDY USING DIRECT COMBINATION DNA INJECTIONS FOR IMMUNOTHERAPY$32,212
M01 · FY2000 · RR
PHASE I STUDY USING DIRECT COMBINATION DNA INJECTIONS FOR IMMUNOTHERAPY$0
M01 · FY2000 · RR